Abstract 4606
Background
ENZA, a potent androgen receptor inhibitor, provides benefit in men with castration-resistant prostate cancer (CRPC). In post hoc analyses, the role of ENZA + ADT in mHSPC patients (pts) randomized within the multinational, double-blind, PBO-controlled, Phase 3 ARCHES study (NCT02677896) was determined by disease volume and risk group stratification.
Methods
mHSPC pts were randomized 1:1 to ENZA (160 mg/day) + ADT or PBO + ADT. The primary endpoint was radiographic progression-free survival (rPFS). Secondary endpoints included prostate-specific antigen (PSA) progression and radiographic responses, overall survival (OS), and quality of life (QoL). Analyses were completed by CHAARTED-defined disease volume and LATITUDE-defined risk groups.
Results
1150 pts were randomized (ENZA + ADT, n = 574; PBO + ADT, n = 576). Median follow-up was 14.4 months. ENZA + ADT significantly improved rPFS (hazard ratio [95% CI] 0.39 [0.30, 0.50]; p < 0.0001). ENZA + ADT pts significantly benefited from prolonged rPFS in all subgroups (Table). Significant treatment benefits were observed with ENZA + ADT in several secondary clinical endpoints in the overall population and in both high and low disease volume and risk groups (Table). High QoL at baseline was maintained over time. OS data are immature. Adverse events (AEs) were reported in 85.1% of ENZA + ADT vs. 85.9% of PBO + ADT pts, with no unexpected AEs.Table:
853P
Overall (n = 1150) | Low-volume diseasea (n = 423) | High-volume diseasea (n = 727) | Low riskb (n = 556) | High riskb (n = 511) | |
---|---|---|---|---|---|
HR (95% CI)c | |||||
Primary endpoint | |||||
rPFSd | 0.39 (0.30, 0.50) | 0.25 (0.14, 0.46) | 0.43 (0.33, 0.57) | 0.42 (0.28, 0.62) | 0.34 (0.25, 0.47) |
Secondary endpoints | |||||
Time to PSA progression | 0.19 (0.13, 0.26) | 0.08 (0.03, 0.20) | 0.22 (0.16, 0.32) | 0.14 (0.08, 0.25) | 0.21 (0.14, 0.31) |
Time to castration resistance | 0.28 (0.22, 0.36) | 0.18 (0.10, 0.32) | 0.32 (0.24, 0.41) | 0.27 (0.18, 0.39) | 0.27 (0.20, 0.37) |
Time to first SSE | 0.52 (0.33, 0.80) | 0.25 (0.07, 0.91) | 0.59 (0.37, 0.95) | 0.39 (0.19, 0.81) | 0.56 (0.32, 0.98) |
Time to new antineoplastic therapy | 0.28 (0.20, 0.40) | 0.39 (0.18, 0.82) | 0.27 (0.18, 0.40) | 0.28 (0.16, 0.50) | 0.28 (0.18, 0.43) |
Rate difference (95% CI)e | |||||
PSA undetectable (<0.2 ng/mL) rate,f % | 50.5 (45.3, 55.7) | 48.4 (39.3, 57.4) | 50.7 (44.5, 57.0) | 54.7 (47.2, 62.1) | 46.0 (38.5, 53.5) |
ORR,f % | 19.3 (10.4, 28.2) | 21.1 (5.0, 37.3) | 18.6 (7.9, 29.3) | 16.4 (2.9, 29.9) | 21.7 (9.8, 33.5) |
Defined as per CHAARTED trial criteria; high volume is defined as the presence of visceral metastases or ≥ 4 bone lesions with ≥1 beyond the vertebral bodies and pelvis (Sweeney et al, New Engl J Med 2014);
bDefined as per LATITUDE trial criteria; high-risk patients had ≥2 of the following: Gleason score of ≥ 8 (scale of 2–10), ≥3 bone lesions and/or the presence of measurable visceral metastasis (Fizazi et al, New Engl J Med 2017);
cHR < 1 favors ENZA + ADT; HR > 1 favors PBO + ADT;
dAssessed by ICR or death within 24 weeks of treatment discontinuation;
eDifference >0 favors ENZA + ADT; difference <0 favors PBO + ADT;
fOf those with detectable PSA or measurable disease at baseline, respectively. ADT=androgen deprivation therapy; CI=confidence interval; ENZA=enzalutamide; HR=hazard ratio; ICR=independent central review; PBO=placebo; PSA=prostate-specific antigen; ORR=objective response rate; OS=overall survival; QoL=quality of life; rPFS=radiographic progression free survival; SSE=symptomatic skeletal event.
Conclusions
ENZA + ADT treatment showed efficacy benefit across all mHSPC pts, irrespective of disease volume and risk group. Similar delays in rPFS, symptomatic skeletal events, PSA progression, castration resistance, and improvements in radiographic responses and PSA declines, with maintenance of high QoL over time, were observed. Preliminary safety analysis appears consistent with the safety profile of ENZA in previous CRPC clinical trials.
Clinical trial identification
NCT02677896.
Editorial acknowledgement
Beatrice Vetter-Ceriotti and Lauren Smith from Complete HealthVizion, funded by the study sponsors.
Legal entity responsible for the study
Astellas Pharma Inc. and Medivation LLC, a Pfizer Company, the co-developers of enzalutamide.
Funding
Astellas Pharma Inc. and Medivation LLC, a Pfizer Company, the co-developers of enzalutamide.
Disclosure
A. Stenzl: Advisory / Consultancy: Bipsen Pharma; Advisory / Consultancy: Roche; Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Janssen; Advisory / Consultancy: Alere; Advisory / Consultancy: BMS; Advisory / Consultancy: Stebatiotechnology; Research grant / Funding (self): Karl Storz AG; Research grant / Funding (self): Astellas Pharma; Research grant / Funding (self): AstraZeneca; Research grant / Funding (self): Medivation; Travel / Accommodation / Expenses: Ipsen Pharma; Travel / Accommodation / Expenses: Sanofi; Travel / Accommodation / Expenses: Aventis; Travel / Accommodation / Expenses: Curevac; Travel / Accommodation / Expenses: Ferring. R.Z. Szmulewitz: Advisory / Consultancy: AstraZeneca; Advisory / Consultancy, Research grant / Funding (self): AbbVie; Advisory / Consultancy: Exelixis; Advisory / Consultancy: Merck; Advisory / Consultancy: Amgen; Advisory / Consultancy, Research grant / Funding (self): Janssen Oncology; Advisory / Consultancy: Sanofi; Advisory / Consultancy, Research grant / Funding (self): Astellas Pharma; Advisory / Consultancy: Pfizer; Research grant / Funding (self): Incyte; Research grant / Funding (self): Macrogenics; Travel / Accommodation / Expenses: Concept Therapeutics. D.P. Petrylak: Advisory / Consultancy, Shareholder / Stockholder / Stock options: Bellicum; Shareholder / Stockholder / Stock options: Tyme; Advisory / Consultancy: Astellas Pharma; Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Genentech; Research grant / Funding (institution): Merck; Advisory / Consultancy: Exelixis; Advisory / Consultancy: Ferring; Advisory / Consultancy, Research grant / Funding (institution): Johnson & Johnson; Speaker Bureau / Expert testimony: Celgene; Advisory / Consultancy, Research grant / Funding (institution): Medivation, Lilly; Advisory / Consultancy, Research grant / Funding (institution): Millineum, Dendreon, Aventis; Research grant / Funding (institution): Progenics; Advisory / Consultancy, Research grant / Funding (institution): Roche Laboratories; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Sanofi; Research grant / Funding (institution): Innocrin; Research grant / Funding (institution): Agensys; Research grant / Funding (institution): Clovis; Research grant / Funding (institution): Endocyte; Advisory / Consultancy, Research grant / Funding (institution): Pfizer. J. Holzbeierlein: Research grant / Funding (self): Astellas Pharma; Research grant / Funding (self): MDX Health. A. Villers: Advisory / Consultancy: Astellas France; Research grant / Funding (institution): Astellas Pharma. A.A. Azad: Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Astellas Pharma; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Novartis; Advisory / Consultancy, Travel / Accommodation / Expenses: Janssen; Advisory / Consultancy: Sanofi; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy, Travel / Accommodation / Expenses: Tolmar; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Amgen; Speaker Bureau / Expert testimony: Bayer; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Novartis. A. Alcaraz: Travel / Accommodation / Expenses: Astellas; Travel / Accommodation / Expenses: Olympus; Travel / Accommodation / Expenses: Ipsen. B.Y. Alekseev: Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: Astellas Pharma; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: Bayer; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: BMS; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Ferring; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: Janssen; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: MSD; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Sanofi. T. Iguchi: Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Bayer; Advisory / Consultancy, Speaker Bureau / Expert testimony: Janssen; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Astellas Pharma; Speaker Bureau / Expert testimony: Sanofi; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Bayer. N.D. Shore: Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Bayer; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Janssen Scientific Affairs; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Dendreon; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Tolmar; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Ferring; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Medivation/Astellas; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Amgen; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Genentech/Roche; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Myovant Sciences; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Bayer. B. Rosbrook: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer Inc. B. Baron: Advisory / Consultancy, Full / Part-time employment: Astellas. G.P. Haas: Full / Part-time employment: Astellas Pharma. R. Morlock: Advisory / Consultancy: Abbott Medical Optics; Advisory / Consultancy: Ironwood; Advisory / Consultancy: Genentech; Full / Part-time employment: Astellas Pharma. K. Ramaswamy: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer Inc. A.J. Armstrong: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Sanofi; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Dendreon; Honoraria (institution): Janssen Oncology; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Bayer; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution): Medivation; Advisory / Consultancy, Travel / Accommodation / Expenses: Janssen Biotech; Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Advisory / Consultancy, Travel / Accommodation / Expenses: Astellas Scientific & Medical Affairs Inc; Research grant / Funding (institution): Gilead Sciences; Research grant / Funding (institution): Roche/Genentech; Research grant / Funding (institution): Active Biotech; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Astellas Pharma; Research grant / Funding (institution): Janssen.
Resources from the same session
2262 - Real world experience of Nivolumab therapy in Metastatic Renal Cancer patients: a 3 year multi-centre review
Presenter: Joanna Hack
Session: Poster Display session 3
Resources:
Abstract
4441 - “A pilot study of tremelimumab (treme) with or without cryoablation (cryo) in patients (pts) in metastatic renal cell carcinoma (mRCC).”
Presenter: Matthew Campbell
Session: Poster Display session 3
Resources:
Abstract
2613 - Lenvatinib (Len) alone or in combination with Everolimus (Eve) in heavily pretreated patients (pts) with metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitors (ICI) and VEGFR-targeted therapies: A single-institution experience
Presenter: Andrew Wiele
Session: Poster Display session 3
Resources:
Abstract
3249 - Weight loss is an underestimated adverse event with cabozantinib in patients with metastastic renal cell carcinoma (mRCC).
Presenter: Emeline Colomba
Session: Poster Display session 3
Resources:
Abstract
2405 - Impact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma.
Presenter: Felix Lefort
Session: Poster Display session 3
Resources:
Abstract
4020 - Skeletal muscle loss as an adverse event during Cabozantinib treatment in patients with metastatic renal cell carcinoma
Presenter: Carolina Alves Costa Silva
Session: Poster Display session 3
Resources:
Abstract
2407 - Long term relative survival (RS) in patients with primary metastatic kidney cancer (primary mRCC): an analysis of 2,167 patients from the Austrian National Cancer Registry (ANCR).
Presenter: Monika Hackl
Session: Poster Display session 3
Resources:
Abstract
2470 - Advanced renal cell carcinoma: first results from the prospective research platform CARAT for patients with mRCC in Germany
Presenter: Peter Goebell
Session: Poster Display session 3
Resources:
Abstract
1533 - Are immune checkpoint inhibitors a valid option for papillary Renal Cell Carcinoma? Transcriptomic characterization of the immune infiltrate
Presenter: Manon De Vries-brilland
Session: Poster Display session 3
Resources:
Abstract
3367 - Treatment-Free Survival, With and Without Toxicity, as a Novel Outcome Applied to Immuno-Oncology Agents in Advanced Renal Cell Carcinoma
Presenter: Meredith Regan
Session: Poster Display session 3
Resources:
Abstract